Solid Biosciences (SLDB) Depreciation & Amortization (CF) (2017 - 2026)

Solid Biosciences has disclosed Depreciation & Amortization (CF) across 10 years of filings, most recently posting $395000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $395000.0, down 2.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 35.94% YoY), and the FY2025 annual result was $1.6 million, down 33.36% from the prior year.
• Depreciation & Amortization (CF) came in at $395000.0 for Q1 2026 at Solid Biosciences, down from $467000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q2 2024 to a low of $327000.0 in Q1 2024.
• The 5-year median for Depreciation & Amortization (CF) is $488000.0 (2024), against an average of $557352.9.
• Across the five-year window, Depreciation & Amortization (CF) jumped 75.68% in 2024 and slumped 68.74% in 2025, its largest moves.
• Solid Biosciences' Depreciation & Amortization (CF) stood at $539000.0 in 2022, then increased by 8.91% to $587000.0 in 2023, then retreated by 16.87% to $488000.0 in 2024, then fell by 4.3% to $467000.0 in 2025, then fell by 15.42% to $395000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $395000.0 (Q1 2026), $467000.0 (Q4 2025), and $376000.0 (Q3 2025), per Business Quant data.